BioLargo (OTCQX: BLGO) loses top client but grows new segments

Rhea-AI Filing Summary

BioLargo, Inc. used this report to share an investor slide deck and press release summarizing its 2025 performance and outlook. Management described 2025 as a year of both accomplishment and adversity, including the termination of its largest customer’s license and the related loss of revenue.

The company highlighted a $3.9 million cash balance at year end 2025, a 98% increase in engineering services revenue, and commercialization progress across several business segments. Subsidiaries Clyra Medical Technologies and Cellinity Battery raised capital in 2025, and leadership expressed optimism about 2026 opportunities in surgical products, PFAS water treatment, and battery energy storage.

Positive

• None.

Negative

• The termination of BioLargo’s largest customer’s license, and the associated loss of revenue, represents a material setback and increases uncertainty around near-term revenue stability.

Insights

Equity analyst

Loss of largest customer offsets growth and raises risk.

BioLargo reports mixed developments: it lost its largest customer’s license and related revenue, while simultaneously growing engineering services revenue by 98% and advancing commercialization in multiple business segments. Year-end cash was $3.9 million, giving some liquidity but without broader balance sheet context.

Management points to increased enterprise valuations and successful capital raises at Clyra Medical Technologies and Cellinity Battery, plus new opportunities in surgical products, PFAS water treatment, and battery energy storage. However, the loss of the largest customer introduces meaningful revenue uncertainty; how quickly new segments scale in 2026 will be critical to offset that gap.

false 0000880242 0000880242 2026-03-05 2026-03-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2026

BioLargo, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-19709		65-0159115
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

14921 Chestnut St., Westminster, California		92683
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 400-2863

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BLGO	OTCQX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

BioLargo, Inc., intends to present the slides attached as Exhibit 99.1, which are incorporated herein by reference, on March 5, 2026, 9:00 AM Pacific Time, at a webcast investor conference. BioLargo, Inc., published the press released attached as Exhibit 99.2, which is incorporated by this reference, on March 5, 2026.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the exhibits to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading “Safe Harbor Act” in the exhibits attached hereto.

Item 9.01. Financial Statements and Exhibits.

(d)         Exhibits.

Exhibit No.	Description
99.1	Slide deck presentation
99.2	Press release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 5, 2026						BIOLARGO, INC.
						By:		/s/ Dennis P. Calvert
								Dennis P. Calvert
								President and Chief Executive Officer

Exhibit 99.1

Exhibit 99.2

BioLargo Reports Annual 2025 Operating and Financial Results

A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments

$3.9 Million Cash Balance at Year End

Westminster, CA / ACCESS Newswire / March 5, 2026 – BioLargo, Inc. (OTCQX: BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Annual Report for the year ended December 31, 2025. To view the filing in its entirety, please see:

https://www.biolargo.com/sec-filings.

BioLargo, Inc. President and CEO Dennis P. Calvert, commented, “2025 was a year of great accomplishment and great adversity, where, on the one hand, we managed through the termination of our largest customer’s license and that loss of revenue, and, on the other, grew our engineering services revenue by 98%, and advanced our other business projects and divisions. We did what we said we would do, making significant commercial advancements in several business segments, setting the stage for revenues in new areas in 2026.”

Calvert, concluded, “These accomplishments produced increased enterprise valuations in our Clyra Medical Technologies and Cellinity Battery divisions, both of which raised capital in 2025. Our Company remains very healthy with $3.9 million cash balance and varying shots on goal across several industries. We are as optimistic as ever with our emerging solutions surrounding surgical products, water treatment for the global PFAS contamination crisis and battery energy storage technology. We look forward to continuing our commercialization efforts and ramp in 2026.”

2025 and Subsequent 2026 Highlights:

● BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough

o https://www.biolargo.com/post/biolargo-subsidiary-best-featured-in-chemical-engineering-magazine-for-pfas-breakthrough

● BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium

o https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-highlights-key-opinion-leader-presentation-of-exceptional-viaclyr

● BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution

o https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-technologies-secures-first-stocking-order-with-advanced-solution-f

● BioLargo Installs AEC PFAS Treatment System at Lake Stockholm, New Jersey

o https://www.biolargo.com/post/biolargo-installs-aec-pfas-treatment-system-at-lake-stockholm-new-jersey 

Financial highlights

● Assets at December 31, 2025, were $8,311,000, versus $6,785,000 in liabilities, which included $3,883,000 in cash and cash equivalents

● Revenues for 2025 were $7,765,000, versus $17,779,000 in 2024 – engineering services revenues from third parties increased from $1,017,000 to $1,998,000

● Net loss in 2025 was $15,189,000, versus $4,347,000 in 2024

● Cash flow from financing activities was $2,051,000 for BioLargo Inc., $5,745,000 for Clyra Medical, and $425,000 for BioLargo Energy

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

FAQ

What did BioLargo (BLGO) report about its 2025 business performance?

BioLargo described 2025 as a year of both accomplishment and adversity. It managed the termination of its largest customer’s license, grew engineering services revenue by 98%, advanced several business segments toward commercialization, and saw increased enterprise valuations in its Clyra Medical Technologies and Cellinity Battery subsidiaries.

How much cash did BioLargo (BLGO) report at the end of 2025?

BioLargo reported a $3.9 million cash balance at year-end 2025. Management framed the company as “very healthy,” citing this cash position along with diversified business efforts across surgical products, PFAS water treatment, battery energy storage, and other cleantech and life sciences solutions.

How did BioLargo’s engineering services segment perform in 2025?

BioLargo stated that its engineering services revenue grew by 98% in 2025. This strong growth helped offset adverse impacts from losing its largest customer and supported the company’s narrative of expanding commercial traction across multiple environmental and cleantech solution areas during the year.

What major challenge did BioLargo (BLGO) face with its customers in 2025?

BioLargo faced the termination of its largest customer’s license, resulting in a loss of related revenue. Management highlighted this as a key adversity in 2025, emphasizing efforts to compensate through rapid growth in engineering services and commercialization of other business segments and technologies.

Which BioLargo subsidiaries raised capital during 2025?

BioLargo reported increased enterprise valuations and successful capital raises at Clyra Medical Technologies and Cellinity Battery in 2025. These subsidiaries are central to the company’s efforts in surgical products, infection control, and advanced battery energy storage technologies, supporting its broader cleantech growth strategy.

What growth areas is BioLargo (BLGO) emphasizing for 2026?

BioLargo’s CEO expressed optimism for 2026 around emerging solutions in surgical products, water treatment for global PFAS contamination, and battery energy storage. The company plans to continue commercialization efforts and pursue revenue growth from these technologies across multiple industries and applications.

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 PRESENTATION 7.6 KB
• EX-99.2 EXHIBIT 99.2 PRESS RELEASE 15.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 10.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.9 KB